lundi 4 juillet 2016

Onco Actu du 4 juillet 2016

1. Biologie

Microbiome of breast links to breast cancer [The Evolution and Medicine Review]

Lab-grown tumour could hold key to cancer [The Guardian]

4.5 Dép., diag. & prono. - Colorectal

Top 5 reasons people don’t get screened for colorectal cancer [ACS]

5.12 Immunothérapies

Dividing T Cells Inherit Uneven Enzyme Activity - A Potential Target for Improving Cancer Immunotherapy [Johns Hopkins]

5.2 Pharma

GSK announces start of phase I oncology study with its ICOS agonist antibody [GSK]

5.2.3 Pharma - économie

UK healthcare professionals received £340.3 million in benefits from pharma industry in 2015 discloses ABPI [Pharmafile]

5.3 Traitements - FDA, EMA,...

Pazdur Named Acting Director of FDA’s New Cancer Center [The Cancer Letter]

Biden Announces FDA Center of Excellence [The Cancer Letter]

NICE says 'yes' to degarelix for men with prostate cancer [European Pharmaceutical Review]

5.3.4 Traitements - AMM (FDA, EMA)

European Commission Approves Extended Indication For Amgen's Kyprolis Carfilzomib For The Treatment Of Relapsed Multiple Myeloma Patients [Amgen]

5.4 Traitements - Economie

Gilead hikes price of HIV therapies, other drugs by up to 10 percent [STAT]

5.6 ESMO

World GI 2016 Press Release: Anti-Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly Over Placebo [ESMO]

6.10 Politiques

Brexit Implications: EU Funding Received by UK Institutions in the Last Ten Years #BrexitScience [Digital Science]

6.10.1 Politiques (USA)

Biden: What I Learned About Cancer [The Cancer Letter]

Biden’s Moonshot Goals are Flexible Enough to be Realistic [The Cancer Letter]

6.11 Patients

Well: At the End of Life, What Would Doctors Do? [NY Times]

6.7.2 Applis

Think Differentially: Apple’s Forward-Thinking Approach to Privacy in iOS 10 [CDT]

6.9 Controverses

Have 1 in 5 UK academics fabricated data? [Retraction Watch]